GBA2

Chr 9AR

glucosylceramidase beta 2

Also known as: AD035, NLGase, SPG46

The protein is a microsomal beta-glucosidase localized to the endoplasmic reticulum that catalyzes the hydrolysis of bile acid 3-O-glucosides. Biallelic mutations cause spastic paraplegia 46, an autosomal recessive hereditary spastic paraplegia. The pathogenic mechanism involves loss of function of this carbohydrate metabolism enzyme.

OMIMResearchSummary from RefSeq, OMIM, UniProt
LOFmechanismARLOEUF 0.941 OMIM phenotype
Clinical SummaryGBA2
🧬
Gene-Disease Validity (ClinGen)
complex hereditary spastic paraplegia · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.94LOEUF
pLI 0.000
Z-score 1.91
OE 0.72 (0.560.94)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
1.67Z-score
OE missense 0.80 (0.740.87)
440 obs / 550.1 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.72 (0.560.94)
00.351.4
Missense OE0.80 (0.740.87)
00.61.4
Synonymous OE0.92
01.21.6
LoF obs/exp: 39 / 54.2Missense obs/exp: 440 / 550.1Syn Z: 0.94

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

GBA2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →